source
- Pfizer halts Phase 2 trial of PF-06835375 in primary immune thrombocytopeniaPfizer announced that it is stopping its Phase 2 study of the experimental program PF-06835375, which was being evaluated in patients with primary immune thrombocytopenia, a rare autoimmune blood d…
- Midterm ballot measures spotlight abortion, transgender rights and Medicaid expansionVoters in the upcoming midterm elections will weigh a series of state ballot questions that address contentious health topics such as abortion access, transgender health care and the expansion of M…